RxDoctor Payments Data

Peter Taylor, MD

Clinical Cardiac Electrophysiology · Orlando, FLNPI 1053373290

Payments from drug & device makers

$57,375in general payments, 2019–2025

Across 345 payments — averaging $166.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$45K
  • Boston Scientific$5K
  • Kestra Medical Technology Services, Inc.$2K
  • Medtronic$816
  • Novartis$535
  • E.r. Squibb & Sons, L.L.C.$367
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$28,02570%
  • Speaking & faculty fees$1,6504%
  • Travel & lodging$1,2673%
  • Food & beverage$8,81922%
  • Education$1000%
  • Gifts$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,375 in reported general payments places this provider in the 60th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$187,645
Medicare patients
389
Services billed
2,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis21$652,025
EliquisApixaban294$348,225
EntrestoSacubitril/Valsartan78$102,846
FarxigaDapagliflozin Propanediol71$75,483
XareltoRivaroxaban43$57,077
JardianceEmpagliflozin36$55,805
MultaqDronedarone Hcl23$32,913
Dofetilide44$5,461
Flecainide Acetate94$3,837
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$2,255
Metoprolol Succinate182$2,036
Hydralazine Hcl30$1,222
Rosuvastatin Calcium79$1,099
Diltiazem Hcl29$1,085
Amiodarone Hcl57$1,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$169$1,000,250315 claims
NovartisEntresto$535$102,84678 claims
AstraZenecaFarxiga$316$75,48371 claims
Johnson & JohnsonXarelto$154$57,07743 claims
Boehringer IngelheimJardiance$56$55,80536 claims
Sanofi-aventis U.S. LLCMultaq$13$32,91323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →